LBA44 - Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

Autor: Shitara, K. ¹, Van Cutsem, E. ², Bang, Y.-J. ³, Fuchs, C.S. ⁴, Wyrwicz, L. ⁵, Lee, K.W. ⁶, Kudaba, I. ⁷, Garrido, M. ⁸, Cheol Chung, H. ⁹, Castro, H.R. ¹⁰, Mansoor, W. ¹¹, Braghiroli, M I F M ¹², Goekkurt, E. ¹³, Chao, J. ¹⁴, Wainberg, Z.A. ¹⁵, Kher, U. ¹⁶, Shah, S. ¹⁶, Kang, S.P. ¹⁶, Tabernero, J. ¹⁷

Publikováno v: In Annals of Oncology October 2019 30 Supplement 5:v878-v879

Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.

Autor: Satoh T; Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan., Kang YK; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Chao Y; Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan., Ryu MH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea., Kato K; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan., Cheol Chung H; Division of Medical Oncology, Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea., Chen JS; Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan., Muro K; Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Ki Kang W; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Yeh KH; Department of Oncology, National Taiwan University Hospital, and National Taiwan University Cancer Center, Taipei, Taiwan., Yoshikawa T; Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.; Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan., Oh SC; Division of Hematology and Oncology, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea., Bai LY; Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan., Tamura T; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.; Department of Medical Oncology, Kindai University Nara Hospital, Ikoma, Japan., Lee KW; Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea., Hamamoto Y; Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan., Kim JG; School of Medicine, Kyungpook National University, Daegu, South Korea., Chin K; Department of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan., Oh DY; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea., Minashi K; Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan., Cho JY; Department of Medical Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea., Tsuda M; Department of Gastroenterological Oncology, Hyogo Cancer Center, Akashi, Japan., Tanimoto M; Oncology Clinical Development Planning, Oncology Clinical Development Unit, ONO Pharmaceutical Co., Ltd., Osaka, Japan., Chen LT; National Institute of Cancer Research, National Health Research Institutes, and National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan., Boku N; Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. nboku@ncc.go.jp.

Publikováno v: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association [Gastric Cancer] 2020 Jan; Vol. 23 (1), pp. 143-153. Date of Electronic Publication: 2019 May 13.

An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.

Autor: Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, Wenyu Zhu

Publikováno v: Frontiers in Immunology; 2024, p01-09, 9p

Efficacy of timing‑dependent infusion of nivolumab in patients with advanced gastric cancer.

Autor: Tanaka, Toshimitsu^1,2 (AUTHOR), Suzuki, Hiroyuki² (AUTHOR), Yamaguchi, Shotaro^1,2 (AUTHOR), Shimotsuura, Yasutaka^1,2 (AUTHOR), Nagasu, Sachiko^2,3 (AUTHOR), Murotani, Kenta⁴ (AUTHOR), Fujita, Fumihiko³ (AUTHOR), Kawaguchi, Takumi² (AUTHOR), Miwa, Keisuke¹ (AUTHOR) miwa_keisuke@med.kurume-u.ac.jp

Publikováno v: Oncology Letters. Oct2024, Vol. 28 Issue 4, pN.PAG-N.PAG. 1p.

Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study.

Autor: Sano, Akihiko¹ (AUTHOR), Sohda, Makoto¹ (AUTHOR) msohda@gunma-u.ac.jp, Nakazawa, Nobuhiro¹ (AUTHOR), Ubukata, Yasunari¹ (AUTHOR), Kuriyama, Kengo¹ (AUTHOR), Kimura, Akiharu¹ (AUTHOR), Kogure, Norimichi¹ (AUTHOR), Hosaka, Hisashi² (AUTHOR), Naganuma, Atsushi³ (AUTHOR), Sekiguchi, Masanori⁴ (AUTHOR), Saito, Kana⁵ (AUTHOR), Ogata, Kyoichi¹ (AUTHOR), Sakai, Makoto¹ (AUTHOR), Ogawa, Hiroomi¹ (AUTHOR), Shirabe, Ken¹ (AUTHOR), Saeki, Hiroshi¹ (AUTHOR)

Publikováno v: BMC Cancer. 1/3/2022, Vol. 22 Issue 1, p1-12. 12p.